Global Market Direct’s pharmaceuticals report, “Allergan Limited - Product Pipeline Review - 2013” provides data on the Allergan Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Allergan Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Allergan Limited and industry-specific third party sources, put together by Global Markets Direct’s team.
- Allergan Limited - Brief Allergan Limited overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Allergan Limited human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Allergan Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Allergan Limited’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Allergan Limited’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Allergan Limited in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Allergan Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Allergan Limited. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Allergan Limited and identify potential opportunities in those areas.
Table Of Contents
Allergan Limited - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Allergan Limited Snapshot 4 Key Information 4 Key Facts 4 Allergan Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Allergan Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Allergan Limited - Pipeline Products Glance 9 Allergan Limited Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Allergan Limited - Drug Profiles 10 AGN-195263 10 Product Description 10 Mechanism of Action 10 RandD Progress 10 Allergan Limited - Pipeline Products by Route of Administration 11 Allergan Limited - Locations And Subsidiaries 12 Head Office 12 Appendix 13 Methodology 13 Coverage 13 Secondary Research 13 Primary Research 13 Expert Panel Validation 13 Contact Us 14 Disclaimer 14
List of Tables
Allergan Limited, Key Information 4 Allergan Limited, Key Facts 4 Allergan Limited - Pipeline by Indication, 2013 6 Allergan Limited - Pipeline by Stage of Development, 2013 7 Allergan Limited - Monotherapy Products in Pipeline, 2013 8 Allergan Limited - Phase II, 2013 9 Allergan Limited - Pipeline By Route of Administration, 2013 11
List of Figures
Allergan Limited - Pipeline by Indication, 2013 6 Allergan Limited - Pipeline by Stage of Development, 2013 7 Allergan Limited - Monotherapy Products in Pipeline, 2013 8